Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1421-1440 of 1,743 trials

HER2 Positive Esophageal Cancer: HERES Trial

We are studying whether adding trastuzumab to standard chemotherapy and immunotherapy helps patients with HER2 positive esophageal squamous cell carcinoma live longer without disease progression.

Esophageal Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Non-Small Cell Lung Cancer: Chemotherapy Plus Osimertinib Study

We are evaluating if adding osimertinib to standard chemotherapy helps patients with advanced non-small cell lung cancer who have progressed after initial osimertinib treatment. This study compares the new treatment approach to chemotherapy with a placebo.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

KIN-2787: New Oral Drug for Cancer

We are studying the safety and effects of KIN-2787 in patients with BRAF and/or NRAS mutation-positive solid tumors. This research aims to find out how well this new treatment works.

Tumors with BRAF and NRAS Mutations>2 yearsSafety phase (I)Oncology

Gastric Cancer Treatment: GASTRICHIP Trial

We are comparing two surgical treatments for advanced gastric cancer to see if adding chemotherapy during surgery improves survival rates. This study involves patients with specific stages of gastric adenocarcinoma.

Stomach Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology

Complicated Urinary Tract Infections in Children: Vabomere Study

We are studying the safety and effectiveness of Vabomere for children aged 3 months to under 12 years with complicated urinary tract infections. This research aims to improve treatment options for these young patients.

Complicated Urinary Tract InfectionAcute Pyelonephritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

Group B Streptococcus Vaccine: GBS NN/NN2 in Pregnant Women

We are studying the GBS NN/NN2 vaccine to see how long the immune response lasts and how safe it is when given as a booster during a new pregnancy. We also want to understand how well antibodies are passed from mothers to their babies.

Group B Streptococcus Neonatal Sepsis>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboGynecology and ObstetricsInfectious Diseases

Stage IIIA/B NSCLC: New Immunotherapy and Chemotherapy Approach

We are studying a new treatment combining immunotherapy and chemotherapy for patients with resectable stage IIIA/B non-small cell lung cancer. The trial aims to see if this approach improves survival and quality of life compared to standard treatments.

Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Heart Health: Treatment for Frequent PVCs

We are studying whether treating asymptomatic patients with frequent PVCs can prevent future heart function problems. This trial compares treatment options to simple monitoring to see which is more effective.

Premature Ventricular Contractions (PVCs)>2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCardiologyInternal Medicine

Acute Bacterial Skin Infections: IV Oritavancin for Kids

We are studying a single-dose intravenous medication for children with acute bacterial skin infections. The trial aims to assess its safety and how well it works compared to existing treatments.

Acute Bacterial Skin and Skin Structure Infection>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementDermatologyPediatrics

Soft Tissue Sarcoma: Trabectedin with tTF-NGR

We are studying a new treatment combining trabectedin with tTF-NGR for patients with advanced soft tissue sarcoma. The goal is to see if this combination helps patients live longer without disease progression compared to trabectedin alone.

Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncology

Immune Thrombocytopenia: Dexamethasone vs. IVIg

We are studying whether oral dexamethasone is as effective as intravenous immunoglobulin combined with prednisone for adults with immune thrombocytopenia experiencing bleeding. This research may help identify a more convenient treatment option.

Immune Thrombocytopenia>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyInternal Medicine

Lyell Syndrome: Mesenchymal Stromal Cells Treatment

We are testing a new treatment using mesenchymal stromal cells for patients with Lyell syndrome. The study aims to see if this treatment can help improve skin healing and overall health.

Lyell Syndrome>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyHematology

Sepsis Treatment: Hydrocortisone and Fludrocortisone Study

We are investigating whether a combination of hydrocortisone and fludrocortisone can improve outcomes for adults with sepsis in the ICU. This study aims to see if it helps reduce death or ongoing organ issues compared to a placebo.

Sepsis>2 yearsConfirmation phase (III)Investigational MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Bariatric Surgery: Metformin for Diabetes Management

We are studying whether adding metformin to standard care helps people who had bariatric surgery stay diabetes-free longer. This trial focuses on former type 2 diabetes patients and their overall health and quality of life.

Type 2 Diabetes>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Neonatal Hypoxic Ischemic Encephalopathy: Cord Blood Stem Cell Treatment

We are studying the safety and feasibility of using a baby's own cord blood stem cells to treat neonatal hypoxic ischemic encephalopathy. The trial also looks at how this treatment may help prevent long-term neurological problems.

Neonatal Hypoxic-Ischaemic Encephalopathy>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPediatrics

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: LY3962673 Treatment

We are studying a new treatment called LY3962673 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to existing options.

KRAS G12D-mutant Solid Tumors>2 yearsSafety phase (I)Oncology

Liver Cancer: Tislelizumab Immunotherapy Study

We are testing a new immunotherapy for patients with liver cancer and moderate liver function. The study aims to see if it can improve treatment outcomes and quality of life.

Hepatocellular Carcinoma (HCC)>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHepatologyOncology

Beta-Lactam Antibiotics: Precision Dosing in Critically Ill Children

We are studying a new dosing method for beta-lactam antibiotics in critically ill children to see if it helps them reach treatment goals faster than standard dosing. This may also help reduce their time in the hospital.

Systemic Infections>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInfectious DiseasesPediatrics

Obstructive Colon Cancer: Neoadjuvant Chemotherapy Study

We are studying whether two chemotherapy regimens can improve treatment outcomes for patients with obstructive colon cancer after colostomy. The goal is to see if starting chemotherapy before surgery leads to better recovery and survival rates.

Colon Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology